Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2017
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary) ; Mesenchymal stem cell therapy (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Translational Biosciences
- 26 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
- 26 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 26 Apr 2017 Status changed from active, no longer recruiting to withdrawn prior to enrolment.